RxDoctor Payments Data

Jennifer Bennett, MD

Cardiovascular Disease · Tampa, FLNPI 1063493922

Payments from drug & device makers

$4,681in general payments, 2019–2025

Across 54 payments — averaging $86.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Edwards Lifesciences$1K
  • Heartflow, Inc.$254
  • Astellas Pharma US Inc$80
  • Pfizer$78
  • Boston Scientific$38
  • plus $155 from 7 others

What the payments were for

  • Travel & lodging$2,38351%
  • Food & beverage$2,21847%
  • Education$802%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,681 in reported general payments places this provider in the 55th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$248,239
Medicare patients
1,139
Services billed
2,493

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab137$165,409
EliquisApixaban127$159,737
EntrestoSacubitril/Valsartan73$111,019
XareltoRivaroxaban97$105,828
JardianceEmpagliflozin58$80,594
FarxigaDapagliflozin Propanediol49$60,571
Praluent PenAlirocumab30$28,098
OzempicSemaglutide14$16,443
BrilintaTicagrelor12$15,377
Repatha PushtronexEvolocumab13$10,953
Ranolazine ErRanolazine28$4,029
Metoprolol Succinate299$3,488
Rosuvastatin Calcium338$3,355
Atorvastatin Calcium283$3,303
Nebivolol Hcl63$3,277

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$78$159,737127 claims
Johnson & JohnsonXarelto$27$105,82897 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →